Research programme: serotonin 2C receptor agonists - Biovitrum/GlaxoSmithKline
Latest Information Update: 08 Jun 2007
At a glance
- Originator Biovitrum
- Developer Biovitrum; GlaxoSmithKline
- Mechanism of Action Serotonin 2C receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 31 Oct 2002 Biovitrum and GlaxoSmithKline have entered into an agreement to co-develop serotonin 2c receptor agonists for the treatment of obesisty
- 05 Sep 2001 Preclinical development for Obesity in Sweden (Unknown route)